Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Work
Year: 2015
Type: article
Abstract: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell car... more
Source: New England Journal of Medicine
Institutions Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Hadassah Medical Center, Roswell Park Comprehensive Cancer Center, Sidney Kimmel Comprehensive Cancer Center +29 more
Cites: 36
Cited by: 5,313
Related to: 10
FWCI: 471.5
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze